Perspectives on the development of a molecularly targeted agent (Q34710684)

4 August 2017

1 reference

title

Perspectives on the development of a molecularly targeted agent (English)

1 reference

4 August 2017

Brian J Druker

1

0 references

publication date

1 February 2002

1 reference

4 August 2017

1 reference

4 August 2017

1

1 reference

4 August 2017

1

1 reference

4 August 2017

31-36

1 reference

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Chronic myeloid leukemia. Sceptical scientists

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Chronic myelogenous leukemia: biology and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Acute leukaemia in bcr/abl transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Reversibility of acute B-cell leukaemia induced by BCR-ABL1.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

STI571: a paradigm of new agents for cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Chromosome translocations: dangerous liaisons revisited.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900025-9

7 January 2021

10.1016/S1535-6108(02)00025-9

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12086885